A new clinical trial will open in January for dogs with recurrent pyoderma, with three or more episodes of staphlococcal skin infections in the last six months. The infections can be related to known underlying causes such as allergies, or to unknown causes. The Dermatology Section at UW Veterinary Care is investigating the effectiveness of a new staphylococcal vaccine product. The product is intended to prevent recurrent skin infections, helping alleviate the need for repeated courses of antibiotics.
In addition to having at least three episodes of infection in the last 6 months, eligible dogs must have had causes such as hypothyrodism, parasites or food allergies ruled out or under control. Clients will pay for the initial exam, but other charges associated with the trial (including followup visits, diagnostic evaluations, a complete series of allergy tests, and medication costs) will be paid for by the study. The trial for each dog will last approximately 18 weeks, with visits to UW Veterinary Care every six weeks. The clinical trial will be double blinded and placebo controlled.
For more information please call William Oldenhoff, DVM at 608-263-7600 or send an email message to email@example.com.
This study is being funded by Delmont Laboratories, which also funded the first year of Dr. Oldenhoff’s dermatology postgraduate training program.